2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Hemangiosarcoma
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
99
Fluorouracil
90
Capecitabine
86
Radiotherapy
81
Dexamethasone
81
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Drug Therapy
65
Leucovorin
64
Cetuximab
60
Erlotinib Hydrochloride
56
atezolizumab
53
Sorafenib
53
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
SGN-LIV1A
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled